Looking forward, miRNA-based therapies targeting upstream steps of miRNA processing—such as Dicer and DGCR8—may offer novel therapeutic approaches for hematologic malignancies characterized by impaired miRNA biogenesis. Here, DGCR8 is linked to hematologic disorder.